Philips announces first U.S. patient enrolled in ILLUMENATE study of Stellarex 0.014 Drug-Coated Balloon for below-the-knee peripheral artery disease
(WorldNews Netherlands)

`Several studies have shown the safety and durability benefits of the Stellarex balloon,` said Mahmood K. Razavi, MD, FSIR, FSVM, St. Joseph`s Hospital in Orange, CA and principal investigator of the ILLUMENATE BTK study. `This study will look at findings that continue to demonstrate the benefits of the Stellarex 0.014 Drug-Coated Balloon for BTK peripheral artery disease (PAD) and its safety and durability for patients. Given the challenging chronic nature of BTK PAD, we are hoping to find that through sustained patency using Stellarex, we can improve healing, and reduce target lesion revascularization...